ARC Technology(tm) - The Zenith Advantage

Phil Nowell, Global Leader, Aortic Intervention, Cook Medical

Zenith AAA endografts entered the U.S. market in 2003 and were immediately adopted as the graft of choice for many physicians because of their precision delivery and ability to stay where placed. Initial studies showed virtually no migration and extremely low rates of endoleaks or secondary interventions. In 2008, the five-year clinical data demonstrated that Zenith could maintain its early performance, as the graft continued to show rates of migration, endoleaks and secondary intervention near zero.

So what does Zenith have that makes this possible while other grafts on the market continue to "struggle" to remain fixed in place and maintain a good seal?

Zenith AAA endografts have three features that were designed to make it the most effective device on the market: suprarenal stents with offset barbs that engage the aortic wall, radial force that creates a reliable seal, and a longer main body for additional columnar strength. These three features, termed ARC Technology, work in perfect harmony to give Zenith AAA endografts unrivaled performance. For more information on ARC Technology, email This e-mail address is being protected from spambots. You need JavaScript enabled to view it or talk with your local Zenith representative.